Brought to you by 
Pfizer buys Angiosyn in deal based largely on milestones
Jan 2005
Executive Summary
Pfizer is acquiring privately held Angiosyn (develops therapeutics that control angiogenesis) for a small up-front fee, while the majority of the payments on the deal--worth up to $527mm--are based on Angiosyn's successful development of drugs for an ophthalmic indication and a second undisclosed therapeutic area. (Strategic Transactions assumes the up-front payment to be $132mm and the rest in earn-outs.) Pfizer will also pay sales royalties.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
- Acquisition of Private Biotech
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer buys Angiosyn in deal based largely on milestones
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice